Cartesian Therapeutics (RNAC) Depreciation & Amortization (CF) (2015 - 2026)
Cartesian Therapeutics (RNAC) reported Depreciation & Amortization (CF) of $615000.0 for Q1 2026, down 46.8% year-over-year from $1.2 million in Q1 2025, and up 1.15% quarter-over-quarter from $608000.0 in Q4 2025.
Cartesian Therapeutics (RNAC) Depreciation & Amortization (CF) (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has 12 years of Depreciation & Amortization (CF) data on file, last reported at $615000.0 in Q1 2026.
- Depreciation & Amortization (CF) for Q1 2026 came in at $615000.0, down 46.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.4 million (up 13.84% YoY), and the FY2025 annual result was $3.0 million, up 157.08% from the prior year.
- Depreciation & Amortization (CF) advanced to $615000.0 in Q1 2026 per RNAC's latest filing, from $608000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $1.2 million in Q1 2025 and troughed at $176000.0 in Q2 2023.
- A 5-year average of $403235.3 and a median of $345000.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2023 and 2025: Depreciation & Amortization (CF) tumbled 48.99% in 2023, then jumped 531.69% in 2025.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $241000.0 in 2022, then increased by 12.86% to $272000.0 in 2023, then jumped by 78.68% to $486000.0 in 2024, then advanced by 25.1% to $608000.0 in 2025, then rose by 1.15% to $615000.0 in 2026.
- Business Quant data shows RNAC's Depreciation & Amortization (CF) at $615000.0 in Q1 2026, $608000.0 in Q4 2025, and $606000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Cartesian Therapeutics | 261.84 Mn | 261.84 Mn | - | 615,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 615,000.00 |
| Mar 31, 2026 | 615,000.00 |
| Dec 31, 2025 | 608,000.00 |
| Dec 31, 2025 | 608,000.00 |
| Sep 30, 2025 | 606,000.00 |
| Sep 30, 2025 | 606,000.00 |
| Jun 30, 2025 | 589,000.00 |
| Jun 30, 2025 | 589,000.00 |
| Mar 31, 2025 | 1.16 Mn |
| Mar 31, 2025 | 1.16 Mn |
| Dec 31, 2024 | 486,000.00 |
| Dec 31, 2024 | 486,000.00 |
| Sep 30, 2024 | 286,000.00 |
| Sep 30, 2024 | 286,000.00 |
| Jun 30, 2024 | 196,000.00 |
| Jun 30, 2024 | 196,000.00 |
| Mar 31, 2024 | 183,000.00 |
| Mar 31, 2024 | 183,000.00 |
| Dec 31, 2023 | 272,000.00 |
| Dec 31, 2023 | 272,000.00 |